Key clinical point: Apremilast remains effective and safe for treatment of oral ulcers in Behçet’s disease through 64 weeks.
Major finding: During 64 weeks, only 12% of patients discontinued apremilast because of a treatment-emergent adverse event.
Study details: This 52-week extension of the phase 3, 12-week RELIEF trial included 176 patients with Behçet’s disease.
Disclosures: The presenter reported receiving research funding from and serving as a consultant to Celgene, the study sponsor.
Mahr A. EADV 2019.